On Friday, Edwards Lifesciences Corp (NYSE: EW) opened higher 0.79% from the last session, before settling in for the closing price of $67.01. Price fluctuations for EW have ranged from $58.93 to $96.12 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 10.28% over the past five years. Company’s average yearly earnings per share was noted 2.48% at the time writing. With a float of $591.62 million, this company’s outstanding shares have now reached $601.10 million.
Let’s look at the performance matrix of the company that is accounted for 19800 employees. In terms of profitability, gross margin is 77.85%, operating margin of 27.19%, and the pretax margin is 27.59%.
Edwards Lifesciences Corp (EW) Insider Updates
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Edwards Lifesciences Corp is 1.79%, while institutional ownership is 85.38%. The most recent insider transaction that took place on Oct 15 ’24, was worth 347,534. In this transaction CVP,Strategy/Corp Development of this company sold 5,000 shares at a rate of $69.51, taking the stock ownership to the 46,936 shares. Before that another transaction happened on Sep 11 ’24, when Company’s CVP,Strategy/Corp Development sold 5,000 for $66.77, making the entire transaction worth $333,826. This insider now owns 46,936 shares in total.
Edwards Lifesciences Corp (EW) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 2.48% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.00% during the next five years compared to 15.35% growth over the previous five years of trading.
Edwards Lifesciences Corp (NYSE: EW) Trading Performance Indicators
Check out the current performance indicators for Edwards Lifesciences Corp (EW). In the past quarter, the stock posted a quick ratio of 2.87. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.98. Likewise, its price to free cash flow for the trailing twelve months is 71.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 6.93, a number that is poised to hit 0.55 in the next quarter and is forecasted to reach 2.45 in one year’s time.
Technical Analysis of Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (NYSE: EW) saw its 5-day average volume 6.73 million, a positive change from its year-to-date volume of 4.65 million. As of the previous 9 days, the stock’s Stochastic %D was 26.28%. Additionally, its Average True Range was 2.12.
During the past 100 days, Edwards Lifesciences Corp’s (EW) raw stochastic average was set at 23.71%, which indicates a significant increase from 23.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.55% in the past 14 days, which was lower than the 64.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $67.94, while its 200-day Moving Average is $80.47. Nevertheless, the first resistance level for the watch stands at $68.53 in the near term. At $69.51, the stock is likely to face the second major resistance level. The third major resistance level sits at $70.44. If the price goes on to break the first support level at $66.61, it is likely to go to the next support level at $65.68. Assuming the price breaks the second support level, the third support level stands at $64.70.
Edwards Lifesciences Corp (NYSE: EW) Key Stats
There are currently 602,400K shares outstanding in the company with a market cap of 41.01 billion. Presently, the company’s annual sales total 6,005 M according to its annual income of 1,402 M. Last quarter, the company’s sales amounted to 1,354 M and its income totaled 3,071 M.
